InSite Vision, Inc. is a development‐stage in‐vitro diagnostics company specializing in rapid molecular assays for infectious ocular diseases. The company’s core focus is on leveraging real‐time polymerase chain reaction (PCR) technology to detect bacterial pathogens responsible for eye infections, with an emphasis on delivering timely, actionable results to clinicians.
The company’s lead products include CE-marked real-time PCR assays designed to differentiate between Chlamydia trachomatis and Neisseria gonorrhoeae in ocular specimens. These assays are engineered for integration into standard laboratory workflows, enabling clinical laboratories and ophthalmology clinics to streamline pathogen identification and support more targeted treatment decisions.
Headquartered in Alameda, California, InSite Vision served markets in North America and Europe through a combination of direct sales efforts and distributor partnerships. The company pursued regulatory clearances in key geographies and collaborated with clinical laboratories, hospitals, and ophthalmic practices to facilitate the adoption of its diagnostic platforms.
Founded in 1992, InSite Vision assembled a leadership team with extensive expertise in molecular diagnostics and ophthalmic testing. In April 2014, the company was acquired by Becton Dickinson, a strategic move that integrated InSite Vision’s molecular platforms into BD’s broader portfolio of point‐of‐care diagnostic solutions and expanded the reach of its technologies within clinical settings.
AI Generated. May Contain Errors.
